Market Place
Sourcing Support
Newron presents H1 2024 results and provides business update
19 Sep 2024 //
BUSINESSWIRE
Newron Pharmaceuticals Reports on Its 2024 Investor Day in New York City
25 Jun 2024 //
BUSINESSWIRE
Newron Pharmaceuticals 2024 Investor Day On June 25 In NYC
18 Jun 2024 //
BUSINESSWIRE
Newron Pharma: 2024 Investor Day In New York On June 25
05 Jun 2024 //
BUSINESSWIRE
Newron schizophrenia add-on improves positive, negative symptoms
30 Apr 2024 //
FIERCE BIOTECH
Data from Newron’s Study and An Evenamide Clinical Outlook Presented at The SIRS
08 Apr 2024 //
BUSINESSWIRE
Newron Presents 2023 Financial Results and Provides 2024 Outlook
19 Mar 2024 //
BUSINESSWIRE
Newron Reports Exceptional One-year Results of Study 014/15 With Evenamide
04 Jan 2024 //
BUSINESSWIRE
Newron Completes Enrollment of Schizophrenia Patients in Study 008A
29 Dec 2023 //
BUSINESSWIRE
Newron TRS Study 6 Months’ Results
09 Oct 2023 //
BUSINESSWIRE
Newron to Present Three Posters on Its Clinical Program Evaluating Evenamide
04 Oct 2023 //
BUSINESSWIRE
Newron Announces H1 2023 Results and Provides R&D Update
04 Aug 2023 //
BUSINESSWIRE
Newron Presents Exciting New Data From Study 014/015 at CINP World Congress
15 May 2023 //
BUSINESSWIRE
Newron reports additional data from study 014/015 of TRS therapy
15 May 2023 //
CLINICAL TRIALS ARENA
Newron to present at the 34th CINP World Congress of Neuropsychopharmacology2023
03 May 2023 //
BUSINESSWIRE
Newron announces Senior Management Team changes
02 May 2023 //
PHARMIWEB
Newron Presents Data From First 100 Patients Randomized in Study 014/015
28 Mar 2023 //
BUSINESSWIRE
Newron Reports Compelling Topline Results From All Patients in Study 014
20 Mar 2023 //
BUSINESSWIRE
Newron to present at the 31st European Congress of Psychiatry
17 Mar 2023 //
BUSINESSWIRE
Newron Announces 2022 Financial Results and Provides Outlook For 2023
14 Mar 2023 //
BUSINESSWIRE
Newron Reports Striking Results From PII Clinical Trial Evaluating Evenamide
16 Feb 2023 //
BUSINESSWIRE
Newron`s schizophrenia data boosts chances of historic approval
16 Feb 2023 //
FIERCE BIOTECH
Newron reports results from treatment-resistant schizophrenia therapy trial
03 Jan 2023 //
CLINICAL TRIALS ARENA
Newron striking six-month interim results from its exploratory trial evenamide
03 Jan 2023 //
BUSINESSWIRE
Newron provides H1 2022 results and updates on R&D and business activities
15 Sep 2022 //
BUSINESSWIRE
Newron Extends Senior Management Team and Strengthens Commitment to ESG
01 Jul 2022 //
BUSINESSWIRE
Newron presents encouraging interim results for evenamide in TRS
07 Jun 2022 //
BUSINESSWIRE
JSR Life Sciences’ Amsphere A3 Integrated into the Commercial Manufacturing
22 Mar 2022 //
BUSINESSWIRE
Newron Receives 5th Tranche from Financing Agreement with EIB
18 Oct 2021 //
BUSINESSWIRE
Newron Announces Half-Year 2021 Results
16 Sep 2021 //
BUSINESSWIRE
Newron commences trial of evenamide in schizophrenia patients
07 Sep 2021 //
CLINICALTRIALSARENA
Newron Gets Fourth Tranche from Financing Agreement with EIB
06 Sep 2021 //
FIRSTWORD PHARMA
Newron Initiates Pivotal Study with Evenamide in Patients with Schizophrenia
06 Sep 2021 //
BUSINESSSWIRE
Newron Receives 4th Tranche from Financing Agreement with EIB
06 Sep 2021 //
BUSINESSSWIRE
Newron Announces Paragraph IV ANDA Filings for Xadago (safinamide) in the USA
20 May 2021 //
BUSINESSWIRE
Newron & Zambon sign agreement for potentially pivotal study with safinamide
12 May 2021 //
PRESS RELEASE
Newron Announces Paragraph IV ANDA Filing for Xadago (safinamide) in the USA
04 May 2021 //
BIOSPACE
Newron Announces Results of Explanatory Studies With Evenamide
01 Apr 2021 //
BUSINESSWIRE
Newron Announces Results of Explanatory Studies With Evenamide
31 Mar 2021 //
BUSINESSWIRE
Newron and Zambon Sign Agreement for Potentially Pivotal Study with safinamide
15 Mar 2021 //
BUSINESSWIRE
Newron and Zambon Sign Agreement for Potentially Pivotal Study
15 Mar 2021 //
BUSINESSWIRE
Newron Completes Enrollment of Explanatory Safety and Efficacy Study Evenamide
21 Jan 2021 //
BUSINESSWIRE
Newron Completes Enrollment of Explanatory Safety and Efficacy Study Evenamide
21 Jan 2021 //
BIOSPACE
Treatment-resistant rare diseases: exploring landmark drug approvals in 2020
29 Sep 2020 //
PHARMACEUTICAL TECHNOLOGY
Newron Announces Half-Year 2020 Results
15 Sep 2020 //
BUSINESSNEWS WIRE
Newron Pharmaceuticals Provides Clinical and Business Update
11 Aug 2020 //
BUSINESSWIRE
Newron Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
29 May 2020 //
BUSINESSWIRE
Rett failure sets up thin pipeline
04 May 2020 //
EVALUATE
Newron Reports Top-Line Results From Its STARS Study Evaluating Sarizotan
04 May 2020 //
BUSINESSWIRE
Newron`s Merck KGaA-in licensed compound fails Rett Syndrome study, shares wilt
04 May 2020 //
ENDPTS
Newron Receives Third Tranche from Financing Agreement with (EIB)
15 Apr 2020 //
BUSINESSWIRE
Newron announce successful results from schizophrenia study
05 Apr 2020 //
PHARMAFILE
Newron Updates On STARS Study FDA Interaction
10 Mar 2020 //
BUSINESS WIRE
Tiziana Reports Phase 1 Clinical Data Demonste Oral Treatment with Foralumab
09 Jan 2020 //
BUSINESS WIRE
Italian Biopharm Requests Type A FDA Meeting to Discuss Statistical Plan
12 Dec 2019 //
PHARMATECH
Newron to Request Type A FDA Meeting Prior Unblinding of STARS Clinical Data
09 Dec 2019 //
BUSINESSWIRE
Newron`s safinamide OK`d in Japan for Parkinson`s
20 Sep 2019 //
SEEKINGALPHA
Newron Receives First Tranche from Financing Agreement with EIB
28 Jun 2019 //
BIOSPACE
Newron delays pivotal schizophrenia trials amid safety fears
29 May 2019 //
FIERCE BIOTECH
Newron Provides Update on STARS Clinical Study with Sarizotan Rett Syndrome
13 Jun 2018 //
BUSINESSWIRE
